MC# 20-06 - A Phase I, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors

  • Agent(s): SRK-181
  • Disease Type(s): Bladder, Melanoma, Solid Tumor, Lung-NSCLC
  • Phase(s): I
  • Drug Classification(s): Targeted Therapy, Monoclonal Antibody
  • Molecular Target(s): TGFβ

Mechanism of Action

SRK-181, an anti-latent TGFβ1 monoclonal antibody, is an agent designed to target the latent TGFβ1 complex, preventing TGFβ1 activation in an isoform-specific manner.

Purpose

In this study, the sponsor and investigators want to learn:

  • About the safety and tolerability of SRK-181 alone and in combination with anti-PD-(L)1 treatment
  • Anti-tumor activity of SRK-181, alone or in combination with anti-PD-(L)1 antibody therapy as potential indicators of clinical response
  • How proteins that indicate the status of your disease are affected with use of SRK-181
  • If SRK-181 prevents or delays tumor growth or shrinks existing tumors
  • How much of SRK-181 is absorbed into the blood and how fast it is removed
Inclusion Criteria
  • Be willing and able to read, understand, and sign an Informed Consent Form (ICF)
  • Be age ≥18 years
  • Patient has a histologically documented solid tumor that is metastatic or locally advanced, for which SoC therapy does not exist, has failed in the patient, or is not tolerated by the patient, or for which the patient has been assessed by the Investigator as not being a suitable candidate or otherwise ineligible for the SoC therapy
  • For Part A2 and Part B:
    • Patient must have a history of primary anti-PD-(L)1 antibody nonresponse presenting (based upon the Investigator's assessment) either as progressive disease or stable disease (e.g., not improving, but also not worsening, clinically or radiographically) after at least 3 cycles of treatment with an anti-PD-(L)1 antibody therapy (alone or in combination with chemotherapy) approved for that tumor type
    • Patient must have received their most recent dose of anti-PD-(L)1 antibody therapy within 6 months of enrollment
    • For NSCLC patients who have genomic tumor aberrations for which a targeted therapy is available (e.g., anaplastic lymphoma kinase, EGFR), these patients must have progressed on an approved therapy for these aberrations or did not tolerate an approved therapy for these aberrations, or were not considered suitable candidates/ were otherwise ineligible for an approved therapy for these aberrations
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1 as assessed at Screening
  • Patient must have an Eastern Cooperative Oncology Group performance status (PS) 0-1
  • Patient must have a predicted life expectancy of ≥ 3 months
  • Women of child-bearing potential (WOCBP) must have a negative urine pregnancy test within 72 hours prior to first administration of SRK-181 and a negative urine pregnancy test on the first day of dosing
  • WOCBP and males with female partners of child-bearing potential must agree to use adequate birth control throughout their participation and for 90 days following the last dose of SRK-181
Exclusion Criteria
  • For Part A1 only:
    • Patient has had anti-PD-(L)1 antibody therapy ≤28 days prior to enrollment
    • Patient is receiving concurrent anticancer treatment, including anti-PD-(L)1 antibody therapy, either approved or investigational, within 28 days prior to administration of SRK-181
  • For Part A2 and Part B only:
    • Patient is receiving concurrent anticancer treatment, with the exception of an anti-PD-(L)1 antibody therapy for Part A2 or Part B, either approved or investigational, within 28 days prior to administration of SRK-181
    • Patient has received biologic therapy (except for anti-PD-(L)1 antibody therapy for Part A2 or Part B), <28 days prior to administration of SRK-181
    • Patient has received systemic cytotoxic chemotherapy (except for in combination with anti-PD-(L)1 antibody therapy) <28 days prior to administration of SRK- 181
    • Patient has received targeted small molecule therapy within 5 half-lives of the compound prior to administration of SRK-181
    • Patient has a history of intolerance or treatment discontinuation due to severe irAE or other adverse reaction from prior anti-PD-(L)1 antibody therapy
  • Patient has a hypersensitivity to anti-PD-(L)1 antibody therapy
  • Patient has the documented presence of neutralizing ADA to anti-PD-(L)1 antibody therapy
  • Patient has a diagnosis of immunodeficiency, either primary or acquired
  • Patient is symptomatic or has uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation
  • Patient has current second malignancy at other sites (exceptions: adequately treated in situ carcinoma [e.g., cervical], non-MEL skin cancer, bilateral synchronous discordant breast cancer, or indolent prostate cancer under observation).  A past history of other malignancies is allowed as long as patient has been free of recurrence for ≥2 years, or if the patient has been treated with curative intent within the past 2 years and, in the opinion of the Investigator, is unlikely to have a recurrence.
  • Women who are pregnant or breastfeeding

Location

  • Dallas, TX - Mary Crowley Cancer Research - Medical City
More Info: https://clinicaltrials.gov/show/NCT04291079

Contact Us About This Trial

Reach out to us by sharing your info in the form below or give us a call at 972-566-3000.

Re: MC# 20-06